<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006670</article-id><article-id pub-id-type="pmc">PMC11860609</article-id><article-id pub-id-type="doi">10.3390/vaccines13020123</article-id><article-id pub-id-type="publisher-id">vaccines-13-00123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Immunosuppressive Therapy Modifies Anti-Spike IgG Subclasses Distribution After Four Doses of mRNA Vaccination in a Cohort of Kidney Transplant Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9865-3063</contrib-id><name><surname>Juarez</surname><given-names>Ignacio</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00123" ref-type="corresp">*</xref><xref rid="fn1-vaccines-13-00123" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4644-1277</contrib-id><name><surname>P&#x000e9;rez-Flores</surname><given-names>Isabel</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref><xref rid="fn1-vaccines-13-00123" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Aiffil Meneses</surname><given-names>Arianne S.</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Gomez</surname><given-names>Ana</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Calvo Romero</surname><given-names>Natividad</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8272-0356</contrib-id><name><surname>Rodr&#x000ed;guez-Cubillo</surname><given-names>Beatriz</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Moreno de la Higuera</surname><given-names>Mar&#x000ed;a Angeles</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Peix-Jim&#x000e9;nez</surname><given-names>Bel&#x000e9;n</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez-Garcia</surname><given-names>Raquel</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7296-6504</contrib-id><name><surname>Amor&#x000f3;s-P&#x000e9;rez</surname><given-names>Beatriz</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2584-5125</contrib-id><name><surname>Rivas-Pardo</surname><given-names>Benigno</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Baos-Mu&#x000f1;oz</surname><given-names>Elvira</given-names></name><xref rid="af3-vaccines-13-00123" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Arribi Vilela</surname><given-names>Ana</given-names></name><xref rid="af3-vaccines-13-00123" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0642-8142</contrib-id><name><surname>G&#x000f3;mez Del Moral</surname><given-names>Manuel</given-names></name><xref rid="af4-vaccines-13-00123" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7017-9729</contrib-id><name><surname>S&#x000e1;nchez-Fructuoso</surname><given-names>Ana Isabel</given-names></name><xref rid="af2-vaccines-13-00123" ref-type="aff">2</xref><xref rid="fn2-vaccines-13-00123" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8136-9042</contrib-id><name><surname>Mart&#x000ed;nez-Naves</surname><given-names>Eduardo</given-names></name><xref rid="af1-vaccines-13-00123" ref-type="aff">1</xref><xref rid="fn2-vaccines-13-00123" ref-type="author-notes">&#x02021;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Focosi</surname><given-names>Daniele</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Franchini</surname><given-names>Massimo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00123"><label>1</label>Immunology Department, Complutense University of Madrid, 28040 Madrid, Spain; <email>anlope22@ucm.es</email> (A.L.-G.); <email>beamoros@ucm.es</email> (B.A.-P.); <email>benignor@ucm.es</email> (B.R.-P.); <email>emnaves@ucm.es</email> (E.M.-N.)</aff><aff id="af2-vaccines-13-00123"><label>2</label>Nephrology Department, Institute San Carlos for Medical Research (Instituto de Investigaci&#x000f3;n Sanitaria del Hospital Cl&#x000ed;nico San Carlos (IdISSC)), San Carlos Clinical University Hospital, 28040 Madrid, Spain; <email>perezfloresi@yahoo.es</email> (I.P.-F.); <email>naticalvo75@gmail.com</email> (N.C.R.); <email>brcubillo@gmail.com</email> (B.R.-C.); <email>sanchezfructuoso@gmail.com</email> (A.I.S.-F.)</aff><aff id="af3-vaccines-13-00123"><label>3</label>Microbiology Department, Institute San Carlos for Medical Research (Instituto de Investigaci&#x000f3;n Sanitaria del Hospital Cl&#x000ed;nico San Carlos (IdISSC)), San Carlos Clinical University Hospital, 28040 Madrid, Spain</aff><aff id="af4-vaccines-13-00123"><label>4</label>Department of Cell Biology, Complutense University of Madrid, 28040 Madrid, Spain; <email>mgomezm@med.ucm.es</email></aff><author-notes><corresp id="c1-vaccines-13-00123"><label>*</label>Correspondence: <email>ignajuar@ucm.es</email></corresp><fn id="fn1-vaccines-13-00123"><label>&#x02020;</label><p>I.P.-F. and I.J. share co-first authorship.</p></fn><fn id="fn2-vaccines-13-00123"><label>&#x02021;</label><p>E.M.-N. and A.I.S.-F. share co-senior authorship.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>123</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>20</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: IgG4 is the least immunogenic subclass of IgG. Immunization with mRNA vaccines against SARS-CoV-2, unlike other vaccines, induces an increase in IgG4 against the spike protein in healthy populations. This study investigated whether immunosuppressive therapy affects the immune response, focusing on IgG subclass changes, to four doses of mRNA vaccine in kidney transplant recipients (KTRs). <bold>Methods</bold>: This study includes 146 KTRs and 23 dialysis patients (DPs) who received three mRNA-1273 vaccine doses and a BNT162b2 booster. We evaluated anti-spike IgG titers and subclasses, T-CD4+ and T-CD8+ cellular responses, and serum neutralizing activity (SNA). <bold>Results</bold>: At the fourth dose, 75.8% of COVID-19 na&#x000ef;ve KTRs developed humoral and cellular responses (vs. 95.7% in DPs). There was a correlation between anti-spike IgG titers/subclasses and SNA (<italic toggle="yes">p</italic> &#x0003c; 0.001). IgG subclass kinetics after the third/fourth dose differed between COVID-19 na&#x000ef;ve KTRs and DPs. Immunosuppressive therapy influenced IgG subclasses: mTOR inhibitors (mTORi) positively influenced IgG1 and IgG3 (<italic toggle="yes">p</italic> &#x0003c; 0.05), while mycophenolic acid negatively affected IgG1, IgG3, and IgG4 (<italic toggle="yes">p</italic> &#x0003c; 0.05). SNA is correlated with breakthrough infections after four doses of vaccine in KTRs. mTORi was the only factor associated with SNA &#x0003e; 65% in na&#x000ef;ve KTRs [4.29 (1.21&#x02013;15.17), <italic toggle="yes">p</italic> = 0.024]. <bold>Conclusions</bold>: KTRs show weaker cellular and humoral immune responses to mRNA vaccines and a class shift towards non-inflammatory anti-S IgG4 upon booster doses. IgG subclasses show a positive correlation with SNA and are influenced by immunosuppression. Increased SNA after four doses of vaccine is protective against infection. mTORi may benefit non-responding KTRs.</p></abstract><kwd-group><kwd>kidney transplant recipients</kwd><kwd>SARS-CoV-2 vaccine</kwd><kwd>serum neutralizing activity</kwd><kwd>IgG subclasses</kwd><kwd>COVID-19</kwd></kwd-group><funding-group><award-group><funding-source>Fundaci&#x000f3;n Mutua Madrile&#x000f1;a</funding-source><award-id>AP177642021</award-id></award-group><award-group><funding-source>Comunidad de Madrid</funding-source><award-id>PR38/21-24</award-id></award-group><funding-statement>This work was supported by grants from Fundaci&#x000f3;n Mutua Madrile&#x000f1;a (Ayudas a la investigaci&#x000f3;n en salud; Grant number AP177642021) to A.I.S.-F. and from Comunidad de Madrid (REACT-UE, ANTICIPA-CM Ref. PR38/21-24) to E.M.-N.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00123"><title>1. Introduction</title><p>Two mRNA vaccines from Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) were the first FDA-approved mRNA vaccines for immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both showed high initial efficacy of around 90% in the general population [<xref rid="B1-vaccines-13-00123" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00123" ref-type="bibr">2</xref>], but we do not know the kinetics of this immunity in the medium and long term and the booster doses needed to maintain immunity. It is currently unknown how these new vaccine formats will affect the long-term B cell and Fc antibody response.</p><p>Some works have documented that, after three doses, immunization was superior in terms of humoral response and neutralizing capacity against several SARS-CoV-2 variants [<xref rid="B3-vaccines-13-00123" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00123" ref-type="bibr">4</xref>]. Knowledge of these data may be even more important in kidney transplant recipients (KTRs), as their immunosuppressed status results in a poorer and less durable response than in the general population [<xref rid="B5-vaccines-13-00123" ref-type="bibr">5</xref>].</p><p>Antibodies display multiple functions and features, and are fundamental to the control of viral infection. Neutralizing antibodies and IgG subclasses have been extensively studied as potential markers of disease severity and vaccine efficacy. Recent studies have shown that COVID-19 patients and those receiving vaccination with mRNA-based COVID-19 vaccines develop a robust IgG response in healthy adults, consisting mainly of IgG1 and IgG3 subclasses, with neutralizing activity against SARS-CoV-2 [<xref rid="B6-vaccines-13-00123" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00123" ref-type="bibr">7</xref>].</p><p>However, other authors have observed a significant increase in IgG4 levels after vaccination with the booster doses of the mRNA vaccines, contrary to other antigen expositions, such as adenoviral or inactivated vaccines, or after SARS-CoV-2 infection [<xref rid="B8-vaccines-13-00123" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00123" ref-type="bibr">9</xref>]. To the best of our knowledge, it is unknown whether this shift towards IgG4 production occurs when vaccinating individuals who are being treated with immunosuppressants.</p><p>IgG is the most prevalent immunoglobulin isotype in human serum and plays a pivotal role in the adaptive and innate immune responses. IgG subclasses have unique functional properties that are essential for host defense against infections [<xref rid="B10-vaccines-13-00123" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00123" ref-type="bibr">11</xref>]. These subclasses exhibit different affinities for Fc gamma receptors (Fc&#x003b3;Rs) and for C1q complement binding [<xref rid="B12-vaccines-13-00123" ref-type="bibr">12</xref>], which modulate their ability to trigger effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) [<xref rid="B13-vaccines-13-00123" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00123" ref-type="bibr">14</xref>].</p><p>IgG1 is the most prevalent subclass in serum and has a high affinity for Fc&#x003b3;RI, Fc&#x003b3;RIIa, and Fc&#x003b3;RIIIa expressed on phagocytic and natural killer (NK) cells [<xref rid="B15-vaccines-13-00123" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00123" ref-type="bibr">16</xref>]. This subclass is associated with Th2-type responses and is involved in the clearance of extracellular pathogens by ADCC and complement activation [<xref rid="B17-vaccines-13-00123" ref-type="bibr">17</xref>]. IgG2 has a lower affinity for Fc&#x003b3;Rs but a higher affinity for C1q [<xref rid="B18-vaccines-13-00123" ref-type="bibr">18</xref>] and is critical for opsonization of encapsulated bacteria. IgG3 has the highest affinity for Fc&#x003b3;Rs and is the most potent activator of ADCC and complement activation, while IgG4 has the lowest affinity for Fc&#x003b3;Rs and C1q, is associated with immune tolerance, and is involved in the suppression of allergic and autoimmune reactions [<xref rid="B12-vaccines-13-00123" ref-type="bibr">12</xref>].</p><p>The kinetics of IgG subclasses may explain the variable humoral response observed in some individuals following vaccination. Investigating the dynamics of IgG subclasses is essential for understanding the mechanisms of protection against viral infection, especially in immunosuppressed populations. The aim of this study was to investigate the kinetics of anti-spike antibodies, serum neutralizing activity (SNA), and IgG1-IgG4 subclasses in a cohort of KTRs receiving four doses of mRNA vaccines, to analyze the effect of immunosuppressive therapy and to compare their response with that of another group of dialysis patients (DPs).</p></sec><sec sec-type="methods" id="sec2-vaccines-13-00123"><title>2. Methods</title><sec id="sec2dot1-vaccines-13-00123"><title>2.1. Study Design and Sample Collection</title><p>We conducted a prospective study involving a cohort comprising 146 KTRs who received three doses of mRNA-1273 vaccine at 0, 1, and 5 months and a booster dose of BNT162b2 vaccine at 11 months after the first dose. For comparison purposes, an additional cohort of 23 DPs who received the same vaccination regimen was included. Individuals who had previously been infected with SARS-CoV-2 or who became infected during the follow-up period were excluded from the initial vaccine effectiveness analysis.</p><p>Blood samples were collected two months after the fourth dose (P4). Previous sample data were obtained from samples collected in a previous study [<xref rid="B5-vaccines-13-00123" ref-type="bibr">5</xref>], corresponding to before vaccination (P0), 21 days after the second dose (P1), three months after the second dose (P2), and two months after the third (P3) and fourth dose (P4). Eight months after the fourth dose, we assessed patients who remained uninfected (na&#x000ef;ve KTR) or had a breakthrough infection. The study design and sampling schedule are summarized in <xref rid="vaccines-13-00123-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec2dot2-vaccines-13-00123"><title>2.2. Patient Selection</title><p>KTRs attending the outpatient Renal Transplant Unit between 1 March and 15 April 2021 and expressing a desire to be vaccinated were included in this study. Inclusion criteria included being over 18 years of age, having a history of kidney transplantation for at least six months, and consenting to participate in the study. Exclusion criteria included a history of malignancy, a solid organ transplantation other than kidney, primary immunodeficiency disease, previous allergic reactions to inactivated vaccines, and the presence of an unexplained fever above 37.5 &#x000b0;C or symptoms suggestive of infection.</p><p>The study was conducted in accordance with the ethical standards of the Declaration of Helsinki and was approved by the local ethics committee. Informed written consent was obtained from all participants before blood samples were taken.</p><p>The vaccination periods were carried out following the schedules and periods provided by the Spanish Ministry of Health, including the administration of a booster (4th dose) of the vaccination in individuals undergoing renal transplantation. The vaccination protocol was the same for all participants, including two initial doses of mRNA-1273, and a booster (third dose) of mRNA1237 was performed with 0.25 mL containing 50 &#x003bc;g of mRNA, i.e., half the dose of the initial regimen and a fourth dose of BNT162b2 vaccine (due to stock limitations).</p><p>Samples were taken according to the literature available at the time, although a standard of two months after the booster dose was established for the last samples, based on the results published after one year of analysis of immune responses in the general population.</p></sec><sec id="sec2dot3-vaccines-13-00123"><title>2.3. Control Group Selection</title><p>We established a control group of non-immunocompromised individuals to compare the immune response to the vaccine. This control group consisted of 23 DPs (na&#x000ef;ve to SARS-CoV-2 infection and with no breakthrough infection) who received the same vaccination schedule. Blood samples were collected from the DPs at equivalent time intervals after vaccination under the same conditions as the KTRs.</p></sec><sec id="sec2dot4-vaccines-13-00123"><title>2.4. SARS-CoV-2 Serology Analysis</title><p>A quantitative SARS-CoV-2 IgG test (SARS-CoV-2 IgG II Quant; Abbott Diagnostics) was used according to the manufacturer&#x02019;s instructions. Samples with AU/mL values &#x02265;50 were considered positive for SARS-CoV-2 IgG antibodies. To identify individuals who had been infected with the SARS-CoV-2 before vaccination or between sample collections, we employed an ELISA assay that assessed the presence of anti-SARS-CoV-2 N-protein antibodies, as previously described [<xref rid="B5-vaccines-13-00123" ref-type="bibr">5</xref>].</p><p>The antibody values were converted into WHO binding antibody units (BAU)/mL using a conversion factor of 0.142 (BAU/mL = AU/mL &#x000d7; 0.142).</p></sec><sec id="sec2dot5-vaccines-13-00123"><title>2.5. Assessment of Cell-Mediated Immunity</title><p>Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient isolation, and cells were stimulated with peptides covering the immunodominant domain surface S-protein of SARS-CoV-2. T-cell responses were assessed by flow cytometry using a lower limit of 0.05% as the threshold for a positive cellular response. The reported frequency was obtained by subtracting the background from the negative control for each donor. Antibodies employed were anti-CD3-FITC (UCHT1), CD4-PE (OKT4), and CD8-PE/Cy7 (SK1), and anti-IFN&#x003b3;-APC (B27) (Biolegend), following standard procedures for intracellular staining. The gating strategy and dot-plots are shown in <xref rid="app1-vaccines-13-00123" ref-type="app">Supplementary Figure S1</xref>.</p></sec><sec id="sec2dot6-vaccines-13-00123"><title>2.6. Assessment of Serum Neutralizing Activity of ACE2-RBD</title><p>To determine the serum neutralizing activity (SNA) against the ACE2&#x02013;Spike (RBD) interaction, a competitive ELISA assay was performed as previously described [<xref rid="B5-vaccines-13-00123" ref-type="bibr">5</xref>]. Briefly, plates coated with recombinant RBD and sera samples were incubated with biotin-labeled ACE2 to assess the ACE2-RBD interaction, resulting in a percentage neutralization value.</p></sec><sec id="sec2dot7-vaccines-13-00123"><title>2.7. Measurement of IgG Subclasses</title><p>An ELISA assay for RBD protein was used to measure IgG1, IgG2, IgG3, and IgG4 isotypes. Ninety-six-well plates were coated with SARS-CoV-2 RBD (2 &#x003bc;g/mL) for 16 h at 2 &#x000b0;C, sera samples (1:100 dilution) were incubated, and antibodies were detected using goat anti-human IgG1, IgG2, IgG3 and, IgG4 HRP-conjugated antibodies (SouthernBiotech, Birmingham, AL, USA). Data from these ELISAs are expressed as optical density (OD) at 450 nm.</p><p>To establish the cut-off of anti-S IgG subclasses, we used the value of the mean plus twice the standard deviation (Mean OD + 2 * SD, 95% CI) of the OD value at 430 nm of 8 pre-pandemic sera (PCR negative, anti-S and anti-N total IgG negative, and with no COVID-19 compatible symptoms) per ELISA plate. This methodology is based on the fact that 95.0% of the data are within 1.96 standard deviations of the mean. Therefore, values outside this range are unlikely to be due to random sampling and are significantly higher than the cut-off point value obtained for each IgG isotype. Values above the cut-offs were considered positive. The cut-offs were established as follows: IgG1: 0.0085; IgG2: 0.0075; IgG3: 0.0559; IgG4: 0.018.</p></sec><sec id="sec2dot8-vaccines-13-00123"><title>2.8. Statistical Analysis</title><p>Quantitative data are presented as mean and standard deviation (SD) or median with interquartile range (IQR), while qualitative variables are expressed as absolute and relative frequencies. Categorical variables were compared using the chi-squared test, and continuous variables were analyzed using Student&#x02019;s <italic toggle="yes">t</italic>-test or the Mann&#x02013;Whitney U test, as appropriate. Repeated measures were compared using the Wilcoxon signed-rank test or the McNemar test. Spearman&#x02019;s rho was used to assess the correlations between continuous variables. Logistic regression was used to assess factors associated with immune response, with factors showing a univariate association (<italic toggle="yes">p</italic>-value &#x0003c; 0.100) included in the final multivariate model. All calculations were performed using GraphPad Prism version 8.0 and SPSS version 25.0, with a significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05 (two-tailed).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00123"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-vaccines-13-00123"><title>3.1. Na&#x000ef;ve Kidney Transplant Recipients Have a Lower Response Rate After Fourth Dose of mRNA Vaccine than Dialysis Patients</title><p>The demographic characteristics, immunosuppressive therapy, and laboratory findings of all patients are described in <xref rid="vaccines-13-00123-t001" ref-type="table">Table 1</xref>. Among the COVID-19 na&#x000ef;ve KTRs, 75.8% (69/91) developed a humoral and cellular response after the fourth dose (vs. 95.7% in DPs, <italic toggle="yes">p</italic> &#x0003c; 0.05). Of the remaining 22 (24.2%) na&#x000ef;ve KTRs, 8 patients developed only cell-mediated immunity, 11 developed only a humoral response, and only 3 had no immune response, either cellular or humoral.</p><p>In addition, the intensity of the humoral immune response after the fourth dose was also significantly higher in DPs than in KTRs: anti-spike IgG titers of 23,587 (14,275&#x02013;33,931) vs. 3640 (279&#x02013;15,940) AU/mL, <italic toggle="yes">p</italic> = 0.002; SNA 70.08% (49.14&#x02013;85.96) vs. 29.23% (30.03&#x02013;62.93), <italic toggle="yes">p</italic> = 0.006. However, no differences in the intensity of the cellular response were observed between DPs and KTRs who had a positive response: reactive CD4 T-cell 0.18 (0.03&#x02013;0.49) vs. 0.28% (0.25&#x02013;0.56), <italic toggle="yes">p</italic> = 0.535; reactive CD8 T-cell 0.24 (0.08&#x02013;0.63) vs. 0.15 (0.01&#x02013;0.48), <italic toggle="yes">p</italic> = 0.288.</p></sec><sec id="sec3dot2-vaccines-13-00123"><title>3.2. Kinetics of Anti-Spike IgG Subclasses After Vaccination Against SARS-CoV-2 in Na&#x000ef;ve Kidney Transplant and Dialysis Patient</title><p>In na&#x000ef;ve KTRs, median levels of IgG1 were below the cut-off after P1 and it was increased only after the fourth dose (P4). IgG2 was slightly increased after P2 without further increase in subsequent doses. IgG3 was not detected above the cut-off, while median IgG4 levels were only detected after the fourth dose (P4) (see <xref rid="vaccines-13-00123-t002" ref-type="table">Table 2</xref> and <xref rid="app1-vaccines-13-00123" ref-type="app">Supplementary Figure S2</xref>).</p><p>In na&#x000ef;ve DPs, a decrease in IgG1 levels was observed after the fourth dose compared to the third dose, and IgG4 was the most prevalent IgG subclass.</p><p>Except for IgG1, DPs developed higher levels of the different IgG subclasses than KTRs after four doses of vaccine (<italic toggle="yes">p</italic> &#x0003c; 0.001).</p></sec><sec id="sec3dot3-vaccines-13-00123"><title>3.3. Effect of Immunosuppressive Therapy on the Kinetics of Anti-Spike IgG Subclasses</title><p>Significantly, immunosuppressive therapy had a notable effect on the levels of IgG subclasses in na&#x000ef;ve KTRs. Mycophenolate (MPA) had a negative effect on IgG1, IgG3, and IgG4 subclasses after four doses of vaccine, whereas mTOR inhibitors (mTORi) had a positive correlation with pro-inflammatory subclasses (IgG1 and 3). KTRs treated with MPA exhibited lower levels of IgG1 [0.031 (0.003&#x02013;0.193) vs. 0.127 (0.030&#x02013;0.364), <italic toggle="yes">p</italic> = 0.047], IgG3 [0.011 (0.004&#x02013;0.077) vs. 0.034 (0.020&#x02013;0.100), <italic toggle="yes">p</italic> = 0.039], and IgG4 [0.014 (0.002&#x02013;0.097) vs. 0.329 (0.069&#x02013;0.516), <italic toggle="yes">p</italic> = 0.006] than untreated KTRs (<xref rid="vaccines-13-00123-f002" ref-type="fig">Figure 2</xref>A). Conversely, mTORi treatment showed significantly higher levels of IgG1 [0.153 (0.050&#x02013;0.267) vs. 0.023 (0.004&#x02013;0.137), <italic toggle="yes">p</italic> = 0.014] and IgG3 [0.038 (0.020&#x02013;0.121) vs. 0.010 (0.004&#x02013;0.067), <italic toggle="yes">p</italic> = 0.024] than KTRs without mTORi (<xref rid="vaccines-13-00123-f002" ref-type="fig">Figure 2</xref>B). Moreover, patients treated with mTORi had a significant increase in total anti-S IgG and SNA after the fourth dose (<xref rid="app1-vaccines-13-00123" ref-type="app">Supplementary Figure S3</xref>).</p><p>No association was found between IgG subclasses and age, gender, or other immunosuppressive therapies.</p></sec><sec id="sec3dot4-vaccines-13-00123"><title>3.4. Correlation of Anti-Spike IgG Titers and Subclasses with SNA. Factors Associated with SNA</title><p>A robust correlation was found between the titers of anti-spike IgG and SNA after the fourth dose in na&#x000ef;ve KTRs (r = 0.823, <italic toggle="yes">p</italic> &#x0003c; 0.001). Moreover, a positive correlation was observed between the different IgG subclasses and SNA, with the strongest correlation noted with IgG1 (IgG1: r = 0.706, <italic toggle="yes">p</italic> &#x0003c; 0.001; IgG2: r = 0.358, <italic toggle="yes">p</italic> = 0.007; IgG3: r = 0.529, <italic toggle="yes">p</italic> &#x0003c; 0.001; IgG4: r = 0.502, <italic toggle="yes">p</italic> &#x0003c; 0.001) and with total IgG (r = 0.823 <italic toggle="yes">p</italic> &#x0003c; 0.0001) (<xref rid="vaccines-13-00123-f003" ref-type="fig">Figure 3</xref>).</p><p>Finally, we examined potential factors associated with achieving SNA &#x0003e; 65% after the fourth dose, which represents the 75th percentile of the data set.</p><p>Only mTORi therapy was statistically associated with SNA in COVID-19 na&#x000ef;ve KTRs in the multiple logistic regression analysis. Patients receiving this treatment were more than four times more likely to develop high SNA [4.29 (1.21&#x02013;15.17), <italic toggle="yes">p</italic> = 0.024], as shown in <xref rid="vaccines-13-00123-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot5-vaccines-13-00123"><title>3.5. Impact of Infection Before the Fourth Dose on the Vaccine-Induced Immune Response</title><p>Fifty-five KTRs (37.6%) developed either symptomatic or asymptomatic SARS-CoV-2 breakthrough infection after the booster dose. Seventeen patients had a history of COVID-19 prior to the first vaccine dose, eleven of whom met the criteria for severe COVID-19. Ten KTRs became infected after the second dose of vaccine, while twenty-eight were infected after the third dose (<xref rid="vaccines-13-00123-f001" ref-type="fig">Figure 1</xref>). All patients who became infected after vaccination experienced mild or no symptoms.</p><p>These 55 infected KTRs exhibited a significant increase in anti-spike IgG titers after receiving the fourth dose, as evidenced in <xref rid="vaccines-13-00123-t004" ref-type="table">Table 4</xref> (see <xref rid="app1-vaccines-13-00123" ref-type="app">Supplementary Figure S3c,d</xref> for a visual representation of the data). Furthermore, infected KTRs also showed a higher SNA than na&#x000ef;ve KTRs [30.0 (7.9&#x02013;62.9) vs. 74.4 (51.3&#x02013;82.4)%, <italic toggle="yes">p</italic> &#x0003c; 0.001]. Interestingly, we found that infected KTRs had higher IgG titers for the different IgG subclasses than na&#x000ef;ve patients, although this was statistically significant only for IgG3 [0.016 (0.006&#x02013;0.077) vs. 0.098 (0.055&#x02013;0.222), <italic toggle="yes">p</italic> &#x0003c; 0.001] and IgG4 [0.028 (0.003&#x02013;0.214) vs. 0.155 (0.056&#x02013;0.912), <italic toggle="yes">p</italic> = 0.003]. Regarding the cell-mediated immune response, infected KTRs also showed a higher proportion of reactive CD8 T-cells than their na&#x000ef;ve counterparts (<xref rid="vaccines-13-00123-t004" ref-type="table">Table 4</xref>). No differences in the immune response were observed according to the severity of the infection.</p></sec><sec id="sec3dot6-vaccines-13-00123"><title>3.6. Correlation Between Humoral Immunity and Incidence of Breakthrough Infection After the Fourth Vaccine Dose</title><p>During the six months following P4 (2 months after the fourth dose), 25 of the 91 na&#x000ef;ve KTRs became infected. These 25 patients exhibited a weaker humoral immune response after four doses compared to those who remained uninfected, as evidenced by lower IgG titers and SNA percentage (<xref rid="vaccines-13-00123-t005" ref-type="table">Table 5</xref>).</p><p>Notably, KTRs who achieved an SNA greater than 65% after the fourth dose were almost four times less likely to become infected in the following six months (OR 3.63, 95%CI 0.91&#x02013;14.55, <italic toggle="yes">p</italic> = 0.034).</p><p>Similar results were found for IgG subclasses. Infected KTRs had lower IgG subclass titers compared to non-infected patients, as shown in <xref rid="vaccines-13-00123-t005" ref-type="table">Table 5</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00123"><title>4. Discussion</title><p>Our results showed that KTRs have a high risk of breakthrough infection after the generally scheduled vaccination, even showing suboptimal seropositive protection after the third dose [<xref rid="B5-vaccines-13-00123" ref-type="bibr">5</xref>,<xref rid="B19-vaccines-13-00123" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00123" ref-type="bibr">20</xref>], which led to the recommendation of a fourth dose for these patients. Recent studies suggest that a fourth dose of the mRNA-based Pfizer-BioNTech or Moderna vaccines may offer short-term benefits to individuals with compromised immune systems, particularly kidney transplant recipients (KTRs), by improving immune responses. The World Health Organization has indicated that additional booster doses, such as a second booster, could enhance protection in these populations, although the overall benefit continues to be evaluated [<xref rid="B21-vaccines-13-00123" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00123" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00123" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00123" ref-type="bibr">24</xref>]. However, few studies have evaluated neutralization capacity after the fourth vaccine dose, and none has demonstrated an impact of SNA on breakthrough infection.</p><p>This study tracked antibody and cell-mediated responses in kidney transplant recipients (KTRs) receiving four doses of mRNA vaccines, comparing them with non-immunocompromised individuals undergoing dialysis (DPs). We also analyzed the anti-spike IgG subclass kinetics, which has not been previously reported in this population. Our results showed that repeated mRNA vaccinations in DPs triggered a delayed increase in IgG2 and IgG4 titers, with IgG4 being predominant, while IgG1 titers decreased after the fourth dose, like findings in healthy individuals [<xref rid="B25-vaccines-13-00123" ref-type="bibr">25</xref>]. However, in KTRs we showed that IgG1 titers increased after the second dose, lost the boosting effect after the third dose, and increased again after the fourth dose. Anti-spike IgG4 titers increased gradually after the third and fourth doses, but did not reach the high titers seen in DPs, probably due to the lack of general response shown in total IgG data.</p><p>The robust and sustained induction of anti-spike IgG4 following multiple doses of vaccine may be a consequence of ongoing class switch recombination (CSR) events in Ag-experienced B cells within germinal centers. Irrgang et al. state that the presence of anti-S IgG4 antibodies after the second immunization with the BNT162b2 vaccine indicates that a prolonged period of ongoing B cell maturation may be linked to increased CSR towards distal IgG subclasses. This, in turn, may result in the generation of IgG4-switched memory B cells over time [<xref rid="B26-vaccines-13-00123" ref-type="bibr">26</xref>]. In the present study, which encompassed four doses of mRNA-based vaccines, a comparable shift towards non-inflammatory IgG subclasses was observed. However, it should be noted that the levels and functional profile of spike-specific antibodies induced by the two vaccine types have been documented to exhibit slight disparities [<xref rid="B27-vaccines-13-00123" ref-type="bibr">27</xref>].</p><p>However, the IgG4 response is not a common result of repeated antigen exposure in vaccinations against other microorganisms, nor even of all types of SARS-CoV-2 vaccines. Several years ago, Hendrikx et al. hypothesized that the pronounced IgG4 response after some types of <italic toggle="yes">Pertussis</italic> vaccines could imply a different triggering of the immune system and a Th2 polarization of T-cells [<xref rid="B28-vaccines-13-00123" ref-type="bibr">28</xref>]. Other authors have described that IgG4 kinetics are exclusive to mRNA vaccines, not happening with other classic vaccination procedures, such as adenoviral vectors or inactivated COVID-19 vaccines [<xref rid="B8-vaccines-13-00123" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00123" ref-type="bibr">9</xref>,<xref rid="B29-vaccines-13-00123" ref-type="bibr">29</xref>].</p><p>It is clearly described that IgG4 and IgG2 have a lower potential to mediate Fc&#x003b3;Rs-dependent secondary effector functions, thus being considered non-inflammatory antibodies [<xref rid="B10-vaccines-13-00123" ref-type="bibr">10</xref>]. Whether the striking increase in IgG4 subclass has functional consequences for host defense mechanisms against SARS-CoV-2 infection is still under discussion. Some works have described that hybrid immunity had the highest magnitude and durability of protection [<xref rid="B30-vaccines-13-00123" ref-type="bibr">30</xref>]. In our cohort study, we observed that patients with previous infection receiving four doses of mRNA vaccine had higher SNA and more elevated anti-spike titers, specifically for the IgG4 subclass. In addition, we found evidence that increased anti-spike IgG subclass titers, including IgG4, were associated with increased SNA and a lower rate of breakthrough infection after four doses of vaccine. From these observations, it could be deduced that elevated IgG4 titers should have a positive impact on patients.</p><p>This association between anti-spike IgG4 titers and SNA was not found by Goyins et al., who investigated the antibody response to SARS-CoV-2 in a group of convalescent patients. They observed a moderate correlation between IgG1 and IgG3 and SNA, but no correlation with IgG2 and IgG4 [<xref rid="B31-vaccines-13-00123" ref-type="bibr">31</xref>].</p><p>Another remarkable finding of our study was the relationship between immunosuppressive therapy and the kinetics of anti-spike IgG subclasses. MPA had a negative effect on IgG1, IgG3, and IgG4 subclasses, whereas mTORi had a positive correlation with pro-inflammatory subclasses.</p><p>The use of MPA has been observed to have a negative effect on the efficacy of the SARS-CoV-2 vaccine in kidney transplant recipients (KTRs) and patients with autoimmune diseases, as indicated by a meta-analysis demonstrating that MPA is an independent risk factor for an adverse antibody response following immunization with two vaccine doses in KTRs [<xref rid="B32-vaccines-13-00123" ref-type="bibr">32</xref>]. In a related study, Tang et al. demonstrated that the administration of MPA to patients with systemic lupus erythematosus diminished the serological response to the SARS-CoV-2 vaccine [<xref rid="B33-vaccines-13-00123" ref-type="bibr">33</xref>], suggesting that MPA mitigated the humoral response to vaccination irrespective of the recipient&#x02019;s characteristics. These findings are maintained after the fourth vaccine dose, in contrast to mTORi, which plays a protective role, as we demonstrated in our study; so much so that it is mTOR inhibitors that are mainly responsible for an adequate SNA, which decreases the risk of infection in KTRs.</p><p>The current research on mRNA vaccines has primarily focused on those targeting COVID-19, with several studies observing an increase in IgG4 antibodies associated with repeated mRNA SARS-CoV-2 vaccination and reductions in Fc-mediated antibody-dependent cellular cytotoxicity (ADCP) and antibody-dependent complement deposition (ADCD) that may limit control of viral infection [<xref rid="B34-vaccines-13-00123" ref-type="bibr">34</xref>]. This induction of IgG4 antibodies was not observed after immunization with protein vaccines or adenoviral vectors [<xref rid="B9-vaccines-13-00123" ref-type="bibr">9</xref>,<xref rid="B29-vaccines-13-00123" ref-type="bibr">29</xref>]. These data, along with our own results, set the rationale to use hybrid vaccination as the first-line protocol to induce a highly protective response in immunocompromised patients.</p><p>Finally, other kinds of vaccine against viruses other than SARS-CoV-2 have demonstrated a reduced level of seroprotection in immunocompromised populations. For instance, the influenza vaccine can generate a humoral response in transplant recipients, but with a lower level of protection, despite variable responses [<xref rid="B35-vaccines-13-00123" ref-type="bibr">35</xref>]. A less robust response has also been observed to the respiratory syncytial vaccinations in immunocompromised patients [<xref rid="B36-vaccines-13-00123" ref-type="bibr">36</xref>]. Therefore, the low response to vaccination is not unique to mRNA vaccines, although neither the response with mRNA vaccines nor the hybrid response, which, in our hands, seems to offer more robust responses, was evaluated in these studies.</p><p>This article has several limitations: First, the sample size was reduced, mainly because part of the original study population declined to receive up to four doses of the vaccine, and several of them contracted COVID-19 disease at study end points, forcing early withdrawal from the study. However, the analysis of the SARS-CoV-2 infected population has allowed us to analyze mixed immunity (by vaccination and infection) in this type of patient, as well as to determine the efficacy in terms of safety and post-infection protection of the different doses, as shown by the fact that KTRs who achieved an SNA greater than 65% after the fourth dose were almost four times less likely to become infected in the following six months.</p><p>Second, this paper focuses on the response to vaccination against the virus in its WT strain, as the vaccines administered correspond with the first waves of the pandemic (both BNT162b2 and mRNA-1273). However, in addition to the specific information regarding protection against severe SARS-CoV-2 disease, it is hoped that the data shown in this article can be extrapolated to other mRNA-based vaccines, such as versions for new variants of SARS-CoV-2 or other types of viral infections.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00123"><title>5. Conclusions</title><p>This work describes, for the first time, the dynamics of the immune response following multiple doses of mRNA-based COVID-19 vaccines in KTRs. We show that the administration of a fourth dose of mRNA vaccine significantly enhances the humoral and cellular immune response in KTRs, with a robust and sustained induction of anti-spike IgG4 that positively correlates with SNA and confers protection against breakthrough infection. Furthermore, immunosuppressive therapy has a notable impact on the kinetics of IgG subclasses, with mycophenolate having a negative effect on IgG1, IgG3, and IgG4 levels, whereas mTOR inhibitors exhibit a positive correlation with pro-inflammatory subclasses. Based on the data obtained in this article and other publications linking mTORi to improved response, we believe that non-responders may benefit from switching therapy to include an mTOR inhibitor (such as Everolimus) to increase response to vaccination, provided it is not contraindicated (proteinuria, allergy, or serious adverse effects on previous mTORi treatment).</p><p>In conclusion, these findings underscore the importance of booster vaccination strategies in combination with immunomodulatory treatments and highlight the potential of IgG4 as a key mediator of protective immunity against SARS-CoV-2 in immunocompromised populations such as KTRs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00123"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020123/s1">https://www.mdpi.com/article/10.3390/vaccines13020123/s1</uri>, Figure S1: Dot plot of negative control (DMSO 10%) and SARS-CoV-2 peptide pool to determine cellular response frequency in PBMC from KTR and DP. Figure S2: Graphical representation of IgG subclasses kinetics in KTR an DP donors. Figure S3: IgG kinetics and neutralizing activity in KTR.</p><supplementary-material id="vaccines-13-00123-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00123-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by I.P.-F., I.J., A.A.V., A.L.-G., R.G.-G., B.A.-P., B.R.-P., N.C.R., B.R.-C., M.G.D.M. and B.P.-J. The first draft of the manuscript was written by I.P.-F., I.J., A.A.V., E.M.-N. and A.I.S.-F. A.S.A.M., M.A.M.d.l.H., E.B.-M. and A.I.S.-F. were involved in the follow-up of patients and sample obtention, and I.P.-F., I.J., A.A.V., A.L.-G., R.G.-G., B.A.-P., B.R.-P., N.C.R., B.R.-C., M.G.D.M., B.P.-J., E.M.-N., A.I.S.-F., A.S.A.M., M.A.M.d.l.H. and E.B.-M. commented on previous versions of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The studies involving human participants were reviewed and approved by Ethics Committee of Hospital Cl&#x000ed;nico San Carlos (28 June 2021, 21/200-E).</p></notes><notes><title>Informed Consent Statement</title><p>The patients/participants provided their written informed consent to participate in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00123"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polack</surname><given-names>F.P.</given-names></name>
<name><surname>Thomas</surname><given-names>S.J.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Perez</surname><given-names>J.L.</given-names></name>
<name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>
<name><surname>Moreira</surname><given-names>E.D.</given-names></name>
<name><surname>Zerbini</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00123"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baden</surname><given-names>L.R.</given-names></name>
<name><surname>El Sahly</surname><given-names>H.M.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Kotloff</surname><given-names>K.</given-names></name>
<name><surname>Frey</surname><given-names>S.</given-names></name>
<name><surname>Novak</surname><given-names>R.</given-names></name>
<name><surname>Diemert</surname><given-names>D.</given-names></name>
<name><surname>Spector</surname><given-names>S.A.</given-names></name>
<name><surname>Rouphael</surname><given-names>N.</given-names></name>
<name><surname>Creech</surname><given-names>C.B.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00123"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wratil</surname><given-names>P.R.</given-names></name>
<name><surname>Stern</surname><given-names>M.</given-names></name>
<name><surname>Priller</surname><given-names>A.</given-names></name>
<name><surname>Willmann</surname><given-names>A.</given-names></name>
<name><surname>Almanzar</surname><given-names>G.</given-names></name>
<name><surname>Vogel</surname><given-names>E.</given-names></name>
<name><surname>Feuerherd</surname><given-names>M.</given-names></name>
<name><surname>Cheng</surname><given-names>C.-C.</given-names></name>
<name><surname>Yazici</surname><given-names>S.</given-names></name>
<name><surname>Christa</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>496</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01715-4</pub-id><pub-id pub-id-type="pmid">35090165</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00123"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Cho</surname><given-names>A.</given-names></name>
<name><surname>Gaebler</surname><given-names>C.</given-names></name>
<name><surname>Ben Tanfous</surname><given-names>T.</given-names></name>
<name><surname>DaSilva</surname><given-names>J.</given-names></name>
<name><surname>Bednarski</surname><given-names>E.</given-names></name>
<name><surname>Ramos</surname><given-names>V.</given-names></name>
<name><surname>Zong</surname><given-names>S.</given-names></name>
<name><surname>Johnson</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost</article-title><source>Nature</source><year>2022</year><volume>607</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04778-y</pub-id><pub-id pub-id-type="pmid">35447027</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00123"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Flores</surname><given-names>I.</given-names></name>
<name><surname>Juarez</surname><given-names>I.</given-names></name>
<name><surname>Meneses</surname><given-names>A.S.A.</given-names></name>
<name><surname>Lopez-Gomez</surname><given-names>A.</given-names></name>
<name><surname>Romero</surname><given-names>N.C.</given-names></name>
<name><surname>Rodriguez-Cubillo</surname><given-names>B.</given-names></name>
<name><surname>de la Higuera</surname><given-names>M.A.M.</given-names></name>
<name><surname>Peix-Jim&#x000e9;nez</surname><given-names>B.</given-names></name>
<name><surname>Gonzalez-Garcia</surname><given-names>R.</given-names></name>
<name><surname>Baos-Mu&#x000f1;oz</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1111569</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1111569</pub-id><pub-id pub-id-type="pmid">36817489</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00123"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korobova</surname><given-names>Z.R.</given-names></name>
<name><surname>Zueva</surname><given-names>E.V.</given-names></name>
<name><surname>Arsentieva</surname><given-names>N.A.</given-names></name>
<name><surname>Batsunov</surname><given-names>O.K.</given-names></name>
<name><surname>Liubimova</surname><given-names>N.E.</given-names></name>
<name><surname>Khamitova</surname><given-names>I.V.</given-names></name>
<name><surname>Kuznetsova</surname><given-names>R.N.</given-names></name>
<name><surname>Rubinstein</surname><given-names>A.A.</given-names></name>
<name><surname>Savin</surname><given-names>T.V.</given-names></name>
<name><surname>Stanevich</surname><given-names>O.V.</given-names></name>
<etal/>
</person-group><article-title>Changes in Anti-SARS-CoV-2 IgG Subclasses over Time and in Association with Disease Severity</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>941</elocation-id><pub-id pub-id-type="doi">10.3390/v14050941</pub-id><!--<pub-id pub-id-type="pmcid">PMC9143443</pub-id>--><pub-id pub-id-type="pmid">35632683</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00123"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Bai</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
</person-group><article-title>The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine</article-title><source>Immunology</source><year>2022</year><volume>167</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1111/imm.13531</pub-id><pub-id pub-id-type="pmid">35751471</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00123"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poolchanuan</surname><given-names>P.</given-names></name>
<name><surname>Matsee</surname><given-names>W.</given-names></name>
<name><surname>Sengyee</surname><given-names>S.</given-names></name>
<name><surname>Siripoon</surname><given-names>T.</given-names></name>
<name><surname>Dulsuk</surname><given-names>A.</given-names></name>
<name><surname>Phunpang</surname><given-names>R.</given-names></name>
<name><surname>Pisutsan</surname><given-names>P.</given-names></name>
<name><surname>Piyaphanee</surname><given-names>W.</given-names></name>
<name><surname>Luvira</surname><given-names>V.</given-names></name>
<name><surname>Chantratita</surname><given-names>N.</given-names></name>
</person-group><article-title>Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand</article-title><source>mSphere</source><year>2023</year><volume>8</volume><fpage>e0046522</fpage><pub-id pub-id-type="doi">10.1128/msphere.00465-22</pub-id><pub-id pub-id-type="pmid">36688637</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00123"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Irrgang</surname><given-names>P.</given-names></name>
<name><surname>Gerling</surname><given-names>J.</given-names></name>
<name><surname>Kocher</surname><given-names>K.</given-names></name>
<name><surname>Lapuente</surname><given-names>D.</given-names></name>
<name><surname>Steininger</surname><given-names>P.</given-names></name>
<name><surname>Habenicht</surname><given-names>K.</given-names></name>
<name><surname>Wytopil</surname><given-names>M.</given-names></name>
<name><surname>Beileke</surname><given-names>S.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>S.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination</article-title><source>Sci. Immunol.</source><year>2023</year><volume>8</volume><fpage>eade2798</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.ade2798</pub-id><pub-id pub-id-type="pmid">36548397</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00123"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vidarsson</surname><given-names>G.</given-names></name>
<name><surname>Dekkers</surname><given-names>G.</given-names></name>
<name><surname>Rispens</surname><given-names>T.</given-names></name>
</person-group><article-title>IgG Subclasses and Allotypes: From Structure to Effector Functions</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><elocation-id>520</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id><!--<pub-id pub-id-type="pmcid">PMC4202688</pub-id>--><pub-id pub-id-type="pmid">25368619</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00123"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iles</surname><given-names>J.K.</given-names></name>
<name><surname>Zmuidinaite</surname><given-names>R.</given-names></name>
<name><surname>Sadee</surname><given-names>C.</given-names></name>
<name><surname>Gardiner</surname><given-names>A.</given-names></name>
<name><surname>Lacey</surname><given-names>J.</given-names></name>
<name><surname>Harding</surname><given-names>S.</given-names></name>
<name><surname>Wallis</surname><given-names>G.</given-names></name>
<name><surname>Patel</surname><given-names>R.</given-names></name>
<name><surname>Roblett</surname><given-names>D.</given-names></name>
<name><surname>Heeney</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding&#x02014;Who Is Binding Who and Why?</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>6050</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23116050</pub-id><!--<pub-id pub-id-type="pmcid">PMC9181569</pub-id>--><pub-id pub-id-type="pmid">35682724</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00123"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rispens</surname><given-names>T.</given-names></name>
<name><surname>Huijbers</surname><given-names>M.G.</given-names></name>
</person-group><article-title>The unique properties of IgG4 and its roles in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>763</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00871-z</pub-id><pub-id pub-id-type="pmid">37095254</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00123"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pincetic</surname><given-names>A.</given-names></name>
<name><surname>Bournazos</surname><given-names>S.</given-names></name>
<name><surname>DiLillo</surname><given-names>D.J.</given-names></name>
<name><surname>Maamary</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>T.T.</given-names></name>
<name><surname>Dahan</surname><given-names>R.</given-names></name>
<name><surname>Fiebiger</surname><given-names>B.-M.</given-names></name>
<name><surname>Ravetch</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Type I and type II Fc receptors regulate innate and adaptive immunity</article-title><source>Nat. Immunol.</source><year>2014</year><volume>15</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/ni.2939</pub-id><!--<pub-id pub-id-type="pmcid">PMC7430760</pub-id>--><pub-id pub-id-type="pmid">25045879</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00123"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Taeye</surname><given-names>S.W.</given-names></name>
<name><surname>Bentlage</surname><given-names>A.E.H.</given-names></name>
<name><surname>Mebius</surname><given-names>M.M.</given-names></name>
<name><surname>Meesters</surname><given-names>J.I.</given-names></name>
<name><surname>Lissenberg-Thunnissen</surname><given-names>S.</given-names></name>
<name><surname>Falck</surname><given-names>D.</given-names></name>
<name><surname>S&#x000e9;nard</surname><given-names>T.</given-names></name>
<name><surname>Salehi</surname><given-names>N.</given-names></name>
<name><surname>Wuhrer</surname><given-names>M.</given-names></name>
<name><surname>Schuurman</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Fc&#x003b3;R Binding and ADCC Activity of Human IgG Allotypes</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>740</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00740</pub-id><!--<pub-id pub-id-type="pmcid">PMC7430760</pub-id>--><pub-id pub-id-type="pmid">32435243</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00123"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nimmerjahn</surname><given-names>F.</given-names></name>
<name><surname>Ravetch</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Antibody-mediated modulation of immune responses</article-title><source>Immunol. Rev.</source><year>2010</year><volume>236</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00910.x</pub-id><pub-id pub-id-type="pmid">20636822</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00123"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitzpatrick</surname><given-names>E.A.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Strome</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>496</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00496</pub-id><!--<pub-id pub-id-type="pmcid">PMC7109252</pub-id>--><pub-id pub-id-type="pmid">32269572</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00123"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jefferis</surname><given-names>R.</given-names></name>
<name><surname>Lefranc</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Human immunoglobulin allotypes: Possible implications for immunogenicity</article-title><source>MAbs</source><year>2009</year><volume>1</volume><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.4161/mabs.1.4.9122</pub-id><pub-id pub-id-type="pmid">20073133</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00123"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Idusogie</surname><given-names>E.E.</given-names></name>
<name><surname>Presta</surname><given-names>L.G.</given-names></name>
<name><surname>Gazzano-Santoro</surname><given-names>H.</given-names></name>
<name><surname>Totpal</surname><given-names>K.</given-names></name>
<name><surname>Wong</surname><given-names>P.Y.</given-names></name>
<name><surname>Ultsch</surname><given-names>M.</given-names></name>
<name><surname>Meng</surname><given-names>Y.G.</given-names></name>
<name><surname>Mulkerrin</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc</article-title><source>J. Immunol.</source><year>2000</year><volume>164</volume><fpage>4178</fpage><lpage>4184</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.8.4178</pub-id><pub-id pub-id-type="pmid">10754313</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00123"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Massa</surname><given-names>F.</given-names></name>
<name><surname>Cremoni</surname><given-names>M.</given-names></name>
<name><surname>G&#x000e9;rard</surname><given-names>A.</given-names></name>
<name><surname>Grabsi</surname><given-names>H.</given-names></name>
<name><surname>Rogier</surname><given-names>L.</given-names></name>
<name><surname>Blois</surname><given-names>M.</given-names></name>
<name><surname>Couzin</surname><given-names>C.</given-names></name>
<name><surname>Ben Hassen</surname><given-names>N.</given-names></name>
<name><surname>Rouleau</surname><given-names>M.</given-names></name>
<name><surname>Barbosa</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients</article-title><source>EBioMedicine</source><year>2021</year><volume>73</volume><elocation-id>103679</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103679</pub-id><pub-id pub-id-type="pmid">34763205</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00123"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benning</surname><given-names>L.</given-names></name>
<name><surname>Morath</surname><given-names>C.</given-names></name>
<name><surname>Bartenschlager</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Reineke</surname><given-names>M.</given-names></name>
<name><surname>Beimler</surname><given-names>J.</given-names></name>
<name><surname>Buylaert</surname><given-names>M.</given-names></name>
<name><surname>Nusshag</surname><given-names>C.</given-names></name>
<name><surname>K&#x000e4;lble</surname><given-names>F.</given-names></name>
<name><surname>Reichel</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients</article-title><source>Am. J. Transplant.</source><year>2022</year><volume>22</volume><fpage>1873</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1111/ajt.17054</pub-id><pub-id pub-id-type="pmid">35384272</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00123"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alejo</surname><given-names>J.L.</given-names></name>
<name><surname>Mitchell</surname><given-names>J.M.</given-names></name>
<name><surname>Chiang</surname><given-names>T.P.-Y.</given-names></name>
<name><surname>Abedon</surname><given-names>A.T.B.</given-names></name>
<name><surname>Boyarsky</surname><given-names>B.J.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.</given-names></name>
<name><surname>Levan</surname><given-names>M.L.J.</given-names></name>
<name><surname>Massie</surname><given-names>A.B.</given-names></name>
<name><surname>Garonzik-Wang</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series</article-title><source>Transplantation</source><year>2021</year><volume>105</volume><fpage>e280</fpage><lpage>e281</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000003934</pub-id><pub-id pub-id-type="pmid">34428188</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00123"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benotmane</surname><given-names>I.</given-names></name>
<name><surname>Bruel</surname><given-names>T.</given-names></name>
<name><surname>Planas</surname><given-names>D.</given-names></name>
<name><surname>Fafi-Kremer</surname><given-names>S.</given-names></name>
<name><surname>Schwartz</surname><given-names>O.</given-names></name>
<name><surname>Caillard</surname><given-names>S.</given-names></name>
</person-group><article-title>A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients</article-title><source>Kidney Int.</source><year>2022</year><volume>101</volume><fpage>1073</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2022.02.011</pub-id><pub-id pub-id-type="pmid">35231463</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00123"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caillard</surname><given-names>S.</given-names></name>
<name><surname>Thaunat</surname><given-names>O.</given-names></name>
<name><surname>Benotmane</surname><given-names>I.</given-names></name>
<name><surname>Masset</surname><given-names>C.</given-names></name>
<name><surname>Blancho</surname><given-names>G.</given-names></name>
</person-group><article-title>Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series</article-title><source>Ann. Intern. Med.</source><year>2022</year><volume>175</volume><fpage>455</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.7326/L21-0598</pub-id><pub-id pub-id-type="pmid">35007148</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00123"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Midtvedt</surname><given-names>K.</given-names></name>
<name><surname>Midtvedt</surname><given-names>K.</given-names></name>
<name><surname>Vaage</surname><given-names>J.T.</given-names></name>
<name><surname>Vaage</surname><given-names>J.T.</given-names></name>
<name><surname>Heldal</surname><given-names>K.</given-names></name>
<name><surname>Heldal</surname><given-names>K.</given-names></name>
<name><surname>Munthe</surname><given-names>L.A.</given-names></name>
<name><surname>Munthe</surname><given-names>L.A.</given-names></name>
<name><surname>Lund-Johansen</surname><given-names>F.</given-names></name>
<name><surname>Lund-Johansen</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response</article-title><source>Am. J. Transplant.</source><year>2022</year><volume>22</volume><fpage>2704</fpage><lpage>2706</lpage><pub-id pub-id-type="doi">10.1111/ajt.17091</pub-id><pub-id pub-id-type="pmid">35533010</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00123"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshimura</surname><given-names>M.</given-names></name>
<name><surname>Sakamoto</surname><given-names>A.</given-names></name>
<name><surname>Ozuru</surname><given-names>R.</given-names></name>
<name><surname>Kurihara</surname><given-names>Y.</given-names></name>
<name><surname>Itoh</surname><given-names>R.</given-names></name>
<name><surname>Ishii</surname><given-names>K.</given-names></name>
<name><surname>Shimizu</surname><given-names>A.</given-names></name>
<name><surname>Chou</surname><given-names>B.</given-names></name>
<name><surname>Nabeshima</surname><given-names>S.</given-names></name>
<name><surname>Hiromatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines</article-title><source>Int. J. Infect. Dis.</source><year>2023</year><volume>139</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2023.11.028</pub-id><pub-id pub-id-type="pmid">38029832</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00123"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheehan</surname><given-names>J.</given-names></name>
<name><surname>Ardizzone</surname><given-names>C.M.</given-names></name>
<name><surname>Khanna</surname><given-names>M.</given-names></name>
<name><surname>Trauth</surname><given-names>A.J.</given-names></name>
<name><surname>Hagensee</surname><given-names>M.E.</given-names></name>
<name><surname>Ramsay</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1720</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11111720</pub-id><pub-id pub-id-type="pmid">38006052</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00123"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naranbhai</surname><given-names>V.</given-names></name>
<name><surname>Garcia-Beltran</surname><given-names>W.F.</given-names></name>
<name><surname>Chang</surname><given-names>C.C.</given-names></name>
<name><surname>Mairena</surname><given-names>C.B.</given-names></name>
<name><surname>Thierauf</surname><given-names>J.C.</given-names></name>
<name><surname>Kirkpatrick</surname><given-names>G.</given-names></name>
<name><surname>Onozato</surname><given-names>M.L.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Denis</surname><given-names>K.J.S.</given-names></name>
<name><surname>Lam</surname><given-names>E.C.</given-names></name>
<etal/>
</person-group><article-title>Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines</article-title><source>J. Infect. Dis.</source><year>2021</year><volume>225</volume><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab593</pub-id><pub-id pub-id-type="pmid">34888672</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00123"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hendrikx</surname><given-names>L.H.</given-names></name>
<name><surname>Schure</surname><given-names>R.-M.</given-names></name>
<name><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>K.</given-names></name>
<name><surname>de Rond</surname><given-names>L.G.</given-names></name>
<name><surname>de Greeff</surname><given-names>S.</given-names></name>
<name><surname>Sanders</surname><given-names>E.A.</given-names></name>
<name><surname>Berbers</surname><given-names>G.A.</given-names></name>
<name><surname>Buisman</surname><given-names>A.-M.</given-names></name>
</person-group><article-title>Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6874</fpage><lpage>6880</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.055</pub-id><pub-id pub-id-type="pmid">21803088</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00123"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buhre</surname><given-names>J.S.</given-names></name>
<name><surname>Pongracz</surname><given-names>T.</given-names></name>
<name><surname>K&#x000fc;nsting</surname><given-names>I.</given-names></name>
<name><surname>Lixenfeld</surname><given-names>A.S.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Nouta</surname><given-names>J.</given-names></name>
<name><surname>Lehrian</surname><given-names>S.</given-names></name>
<name><surname>Schmelter</surname><given-names>F.</given-names></name>
<name><surname>Lunding</surname><given-names>H.B.</given-names></name>
<name><surname>D&#x000fc;hring</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine</article-title><source>Front. Immunol.</source><year>2023</year><volume>13</volume><elocation-id>1020844</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1020844</pub-id><pub-id pub-id-type="pmid">36713457</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00123"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bobrovitz</surname><given-names>N.</given-names></name>
<name><surname>Ware</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Hosseini</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Selemon</surname><given-names>A.</given-names></name>
<name><surname>Whelan</surname><given-names>M.</given-names></name>
<name><surname>Premji</surname><given-names>Z.</given-names></name>
<name><surname>Issa</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>556</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00801-5</pub-id><pub-id pub-id-type="pmid">36681084</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00123"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>A Goyins</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>J.-J.</given-names></name>
<name><surname>Papp</surname><given-names>S.B.</given-names></name>
<name><surname>Beddard</surname><given-names>R.</given-names></name>
<name><surname>Murthy</surname><given-names>A.K.</given-names></name>
<name><surname>Chambers</surname><given-names>J.P.</given-names></name>
<name><surname>Arulanandam</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Isotyping and quantitation of the humoral immune response to SARS-CoV-2</article-title><source>Exp. Biol. Med.</source><year>2022</year><volume>247</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1177/15353702221084966</pub-id></element-citation></ref><ref id="B32-vaccines-13-00123"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zong</surname><given-names>K.</given-names></name>
<name><surname>Peng</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xiang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Mou</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>888385</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.888385</pub-id><pub-id pub-id-type="pmid">35774786</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00123"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Gartshteyn</surname><given-names>Y.</given-names></name>
<name><surname>Ricker</surname></name>
<name><surname>Inzerillo</surname><given-names>S.</given-names></name>
<name><surname>Murray</surname><given-names>S.</given-names></name>
<name><surname>Khalili</surname><given-names>L.</given-names></name>
<name><surname>Askanase</surname><given-names>A.</given-names></name>
</person-group><article-title>The Use of COVID-19 Vaccines in Patients with SLE</article-title><source>Curr. Rheumatol. Rep.</source><year>2021</year><volume>23</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s11926-021-01046-2</pub-id><pub-id pub-id-type="pmid">34767100</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00123"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalkeri</surname><given-names>R.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Cloney-Clark</surname><given-names>S.</given-names></name>
<name><surname>Plested</surname><given-names>J.S.</given-names></name>
<name><surname>Parekh</surname><given-names>A.</given-names></name>
<name><surname>Gorinson</surname><given-names>D.</given-names></name>
<name><surname>Cai</surname><given-names>R.</given-names></name>
<name><surname>Mahato</surname><given-names>S.</given-names></name>
<name><surname>Ramanathan</surname><given-names>P.</given-names></name>
<name><surname>Aurelia</surname><given-names>L.C.</given-names></name>
<etal/>
</person-group><article-title>Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines</article-title><source>J. Infect.</source><year>2024</year><volume>88</volume><fpage>106119</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.106119</pub-id><pub-id pub-id-type="pmid">38360356</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00123"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Blumberg</surname><given-names>E.A.</given-names></name>
<name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name>
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Halasa</surname><given-names>N.B.</given-names></name>
<name><surname>Ison</surname><given-names>M.G.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Green</surname><given-names>M.</given-names></name>
<name><surname>Allen</surname><given-names>U.D.</given-names></name>
<name><surname>Edwards</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations</article-title><source>Am. J. Transplant.</source><year>2011</year><volume>11</volume><fpage>2020</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03753.x</pub-id><pub-id pub-id-type="pmid">21957936</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00123"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karaba</surname><given-names>A.H.</given-names></name>
<name><surname>Hage</surname><given-names>C.</given-names></name>
<name><surname>Sengsouk</surname><given-names>I.</given-names></name>
<name><surname>Balasubramanian</surname><given-names>P.</given-names></name>
<name><surname>Segev</surname><given-names>D.L.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.A.R.</given-names></name>
<name><surname>Werbel</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons</article-title><source>JAMA</source><year>2024</year><pub-id pub-id-type="doi">10.1001/jama.2024.25395</pub-id><pub-id pub-id-type="pmid">39786402</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00123-f001"><label>Figure 1</label><caption><p>Flow chart of kidney transplant recipients (KTRs) included in the study and exclusion criteria. Each extraction (P0, P1, P2, P3, and P4) involved the following laboratory determinations: SARS-CoV-2 Serology Analysis, Assessment of Cell-Mediated Immunity, Assessment of Serum Neutralizing Activity of ACE2-RBD, and Measurement of IgG subclasses. Patients were tested for SARS-CoV-2 infection by anti-N antibodies, determined by ELISA.</p></caption><graphic xlink:href="vaccines-13-00123-g001" position="float"/></fig><fig position="float" id="vaccines-13-00123-f002"><label>Figure 2</label><caption><p>Immunosuppressive treatments modulate IgG subtypes in response to SARS-CoV-2 mRNA vaccination after booster dose. (<bold>A</bold>) Mycophenolate mofetil treatment (MPA) decreases IgG1 and IgG4 levels, whereas (<bold>B</bold>) mTOR inhibitors (mTORi) increase IgG1, IgG3, and IgG4 levels in these patients. Untreated condition refers to patients not treated with the analyzed immunosuppressant (e.g., not treated with mTORi, but with other immunosuppression). These findings highlight the distinct immunomodulatory effects of mTORi and MMF on specific IgG subclasses, suggesting possible impacts on treatment efficacy. Only significant <italic toggle="yes">p</italic>-values (&#x0003c;0.05) are shown, * <italic toggle="yes">p</italic>-value &#x0003c; 0.05, ** <italic toggle="yes">p</italic>-value &#x0003c; 0.01. The cut-offs were established as follows: IgG1: 0.0085; IgG2: 0.0075; IgG3: 0.0559; IgG4: 0.018.</p></caption><graphic xlink:href="vaccines-13-00123-g002" position="float"/></fig><fig position="float" id="vaccines-13-00123-f003"><label>Figure 3</label><caption><p>Correlation of IgG subclasses and total IgG levels with serum neutralizing activity (SNA) in kidney transplant recipients. Total IgG (r = 0.823, <italic toggle="yes">p</italic>-value &#x0003c; 0.001) and IgG subclasses showed a positive correlation with SNA, with IgG1 subclass having the higher r-value (0.706, <italic toggle="yes">p</italic>-value &#x0003c; 0.001).</p></caption><graphic xlink:href="vaccines-13-00123-g003" position="float"/></fig><table-wrap position="float" id="vaccines-13-00123-t001"><object-id pub-id-type="pii">vaccines-13-00123-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic characteristics and laboratory findings of kidney transplant recipients and dialysis patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">KTR<break/>(N = 146)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Na&#x000ef;ve KTR<break/>(N = 91)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Infected KTR<break/>(N = 55)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DP<break/>(N = 23)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender (male), N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (62.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (60.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (65.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (56.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ethnicity, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caucasian</td><td align="center" valign="middle" rowspan="1" colspan="1">125 (85.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">79 (86.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (83.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (82.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (13.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (13.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (14.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (13.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">years (mean, SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (15.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.4 (15.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">54.4 (13.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (13)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;60 y, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (58.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (35.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (52.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (34.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (35.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (35.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (34.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HBP, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">132 (90.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (90.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (90.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (100)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cardiovascular disease, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (23.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (23.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (23.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (34.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic lung disease, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (18.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (17.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (20)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (21.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time since transplantation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">years (median, IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.2 (4.0&#x02013;15.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5 (4.4&#x02013;17.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.0 (3.8&#x02013;13.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;5 years, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (28.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (26.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (30.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Previous Transplant,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (13.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (13.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (12.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressive drug, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Steroids</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (48.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (52.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CNI</td><td align="center" valign="middle" rowspan="1" colspan="1">120 (82.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (75.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (92.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MPA</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (76.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (76.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (74.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mTORi</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (28.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (27.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thymoglobulin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82 (56.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53 (58.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (52.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressive protocol, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MPA + CNI</td><td align="center" valign="middle" rowspan="1" colspan="1">102 (69.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">64 (70.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (69.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MPA + mTORi</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (13.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (10.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mTORi + CNI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (17.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (15.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (20.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>), median (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stages CKD, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;60 mL/min/1.73 m<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">49 (33.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (41.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30&#x02013;60</td><td align="center" valign="middle" rowspan="1" colspan="1">71 (48.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (51.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (43.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (17.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (19.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (14.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cells count, 1 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup>, median (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocyte</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52 (1.13&#x02013;2.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 (1.06&#x02013;2.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.70 (1.20&#x02013;2.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 (1.21&#x02013;2.12)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4+ T-cells</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 (0.38&#x02013;0.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 (0.35&#x02013;0.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59 (0.38&#x02013;0.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8+ T-cells</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48 (0.34&#x02013;1.02)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45 (0.29&#x02013;0.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 (0.33&#x02013;0.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphocyte &#x0003e; 1 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107 (73.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 (76.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (67.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (91.3)</td></tr></tbody></table><table-wrap-foot><fn><p>KTR = kidney transplant recipient. DP = dialysis patient. SD = standard deviation. IQR = interquartile ratio. CKD = chronic kidney disease. CNI = calcineurin inhibitor. MPA = mycophenolate acid. mTORi = mammalian target of rapamycin inhibitor. Egfr = estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00123-t002"><object-id pub-id-type="pii">vaccines-13-00123-t002_Table 2</object-id><label>Table 2</label><caption><p>Kinetics of IgG subclasses (median OD 450 nm [IQR]) after vaccination against SARS-CoV-2 in na&#x000ef;ve kidney transplant recipients and dialysis patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">P1</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">P2</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">P3</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">P4</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>IgG1</bold> OD (450 nm)<break/>&#x02003;&#x02003;KTR<break/><break/>&#x02003;&#x02003;DP</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0043<break/>[0.0028&#x02013;0.0067]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0147 <sup>a</sup><break/>[0.0044&#x02013;0.0251]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0117<break/>[0.0035&#x02013;0.1069]<break/>0.0490<break/>[0.0290&#x02013;0.0845]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0470 <sup>b</sup><break/>[0.0103&#x02013;0.1669]<break/>0.0170 <sup>c</sup><break/>[0.0065&#x02013;0.0320]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>IgG2</bold> OD (450 nm)<break/>&#x02003;&#x02003;KTR<break/><break/>&#x02003;&#x02003;DP</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0020<break/>[0.0010&#x02013;0.0035]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0083 <sup>a</sup><break/>[0.005&#x02013;0.0183]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0095<break/>[0.0038&#x02013;0.0226]<break/>0.0260<break/>[0.0218&#x02013;0.0495]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0062<break/>[0.0034&#x02013;0.0214]<break/>0.0530<break/>[0.0123&#x02013;0.0754]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>IgG3</bold> OD (450 nm)<break/>&#x02003;&#x02003;KTR<break/><break/>&#x02003;&#x02003;DP</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0227<break/>[0.0108&#x02013;0.03725]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0323 <sup>d</sup><break/>[0.0115&#x02013;0.0703]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0215<break/>[0.0105&#x02013;0.121]<break/>0.0330<break/>[0.0120&#x02013;0.0470]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0160<break/>[0.007&#x02013;0.0775]<break/>0.0415<break/>[0.0284&#x02013;0.0641]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>IgG4</bold> OD (450 nm)<break/>&#x02003;&#x02003;KTR<break/><break/>&#x02003;&#x02003;DP</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0060<break/>[0.0010&#x02013;0.0093]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0052<break/>[0.0024&#x02013;0.011]<break/>n.d.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0070 <sup>e</sup><break/>[0.0019&#x02013;0.0371]<break/>0.7808<break/>[0.0363&#x02013;1.1873]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0.0285 <sup>f</sup><break/>[0.0048&#x02013;0.1860]<break/>0.8755<break/>[0.1826&#x02013;1.4783]</td></tr></tbody></table><table-wrap-foot><fn><p>P1: At 21 days after 2nd dose. P2: At 3 months after 2nd dose. P3: At 2 months after 3th dose. P4: At 2 months after 4th dose. KTR: kidney transplant recipient (n = 60). DP: dialysis patient (n = 12). <sup>a</sup> IgG1, IgG2 at P1 vs. P2, <italic toggle="yes">p</italic> &#x0003c; 0.001; <sup>b</sup> IgG1 in KTRs at P3 vs. P4, <italic toggle="yes">p</italic> = 0.010; <sup>c</sup> IgG1 in DP at P3 vs. P4, <italic toggle="yes">p</italic> = 0.005; <bold><sup>d</sup></bold> IgG3 at P1 vs. P2, <italic toggle="yes">p</italic> = 0.016; <bold><sup>e</sup></bold> IgG4 in KTRs at P2 vs. P3, <italic toggle="yes">p</italic> = 0.007; <sup>f</sup> IgG4 in KTRs at P3 vs. P4 <italic toggle="yes">p</italic> = 0.001. The cut-offs were established as follows: IgG1: 0.0085; IgG2: 0.0075; IgG3: 0.0559; IgG4: 0.018.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00123-t003"><object-id pub-id-type="pii">vaccines-13-00123-t003_Table 3</object-id><label>Table 3</label><caption><p>Serum neutralizing activity &#x0003e;65% (percentile 75) after 4 doses of vaccine in na&#x000ef;ve KTRs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNA &#x0003e; 65%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Univariate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Multivariate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR (CI 95%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR (CI 95%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81 (0.64&#x02013;5.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.200</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age &#x0003e;60 years</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 (0.48&#x02013;0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49 (0.15&#x02013;1.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.227</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender male</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90 (0.58&#x02013;1.39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.671</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Steroids</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 (0.36&#x02013;0.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 (0.24&#x02013;2.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.764</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CNI</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 (0.71&#x02013;1.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.939</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MPA</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 (0.69&#x02013;1.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.490</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52 (0.13&#x02013;2.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.350</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mTORi</td><td align="center" valign="middle" rowspan="1" colspan="1">5.20 (0.77&#x02013;35.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>4.29 (1.21&#x02013;15.17)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.024</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Thymoglobulin</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 (0.47&#x02013;0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.073</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.25&#x02013;3.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.902</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">eGFR &#x0003e; 30 mL/min</td><td align="center" valign="middle" rowspan="1" colspan="1">3.03 (0.87&#x02013;10.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" rowspan="1" colspan="1">2.89 (0.31&#x02013;26.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.349</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;5 years since transplantation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.68&#x02013;1.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.685</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Previous transplant</td><td align="center" valign="middle" rowspan="1" colspan="1">1.85 (0.49&#x02013;6.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.353</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphocyte &#x0003e; 1 &#x000d7; 10<sup>3</sup>/mm<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97 (0.35&#x02013;2.63)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.953</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>CNI = calcineurin inhibitor. MPA = mycophenolate acid. mTORi = mammalian target of rapamycin inhibitor. eGFR = estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00123-t004"><object-id pub-id-type="pii">vaccines-13-00123-t004_Table 4</object-id><label>Table 4</label><caption><p>Characteristics of specific immunity 2 months after the fourth dose (P4) according to previous SARS-CoV-2 infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Infection Before 4th Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Na&#x000ef;ve KTR (N = 91)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Infected KTR (N = 55)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG SARS-CoV-2 (BAU/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">516.9 (39.6&#x02013;2263.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">3389.1 (1707.6&#x02013;8427.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SNA (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">30.0 (7.9&#x02013;62.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">74.4 (51.3&#x02013;82.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG1 (OD 450 nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047 (0.006&#x02013;0.193)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.078 (0.017&#x02013;0.176)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.450</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG2 (OD 450 nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006 (0.002&#x02013;0.022)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026 (0.003&#x02013;0.056)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.241</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG3 (OD 450 nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016 (0.006&#x02013;0.077)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098 (0.055&#x02013;0.222)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG4 (OD 450 nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028 (0.003&#x02013;0.214)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.155 (0.056&#x02013;0.912)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IFNy-CD4 (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 (0.02&#x02013;0.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31 (0.09&#x02013;0.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.608</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFNy-CD8 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 (0.01&#x02013;0.48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30 (0.15&#x02013;0.83)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr></tbody></table><table-wrap-foot><fn><p>KTR = kidney transplant recipient. SNA = serum neutralizing activity. IFNy = interferon gamma. OD = optical density.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00123-t005"><object-id pub-id-type="pii">vaccines-13-00123-t005_Table 5</object-id><label>Table 5</label><caption><p>Characteristics of specific immunity at P4 between na&#x000ef;ve and infected KTRs at nine months after the fourth dose of the vaccine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Infection After 4th Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Na&#x000ef;ve KTR (N = 66)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Infected KTR (N = 25)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG SARS-CoV-2 (BAU/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1429.7 (63.8&#x02013;2870.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">121.6 (1.0&#x02013;869.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SNA (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">45.8 (8.5&#x02013;69.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">20.3 (1.9&#x02013;46.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.012</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG1 (OD 450 mm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.050 (0.006&#x02013;0.205)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039 (0.000&#x02013;0.060)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.009</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG2 (OD 450 mm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005 (0.002&#x02013;0.037)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002 (0.000&#x02013;0.006)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.006</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG3 (OD 450 mm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017 (0.006&#x02013;0.095)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000 (0.000&#x02013;0.014)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IgG4 (OD 450 mm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032 (0.003&#x02013;0.367)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001 (0.000&#x02013;0.012)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IFNy-CD4 (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 (0.00&#x02013;0.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30 (0.09&#x02013;0.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.373</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFNy-CD8 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17 (0.00&#x02013;0.68)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12 (0.00&#x02013;0.46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.421</td></tr></tbody></table><table-wrap-foot><fn><p>KTR = kidney transplant recipient. SNA = serum neutralizing activity. IFNy = interferon gamma. OD = optical density.</p></fn></table-wrap-foot></table-wrap></floats-group></article>